TY - JOUR
T1 - Prognostication in advanced cancer
T2 - foreseeing from global insights and foretelling in the Asian context
AU - Hiratsuka, Yusuke
AU - Hamano, Jun
AU - Mori, Masanori
AU - Suh, Sang Yeon
AU - Hui, David
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Oxford University Press. All rights reserved.
PY - 2025/9/1
Y1 - 2025/9/1
N2 - Accurate prognostic information is crucial for guiding end-of-life (EOL) decision-making in advanced cancer care. Although the European Society for Medical Oncology (ESMO) recommends using clinicians' prediction of survival (CPS) as an initial reference, CPS alone often lacks precision. This review synthesizes current prognostic models and the dialog surrounding EOL survival prediction. For patients with an expected survival of months, several validated prognostic tools are available, including measures such as the Eastern Cooperative Oncology Group Performance Status, the modified Glasgow Prognostic Scale, and comprehensive models such as the Supportive and Palliative Care Indicator Tool and the adaptable prognosis prediction model. When survival is expected to be weeks, the Palliative Performance Scale serves as a key assessment tool, while models such as the Palliative Prognostic Index and Prognosis in Palliative Care Study models are helpful. In the final days of life, clinicians primarily rely on observable physical indicators, including decreased consciousness and specific breathing patterns, whereas the surprise question has demonstrated limited predictive utility in this context. While most patients with advanced cancer express a desire for prognostic information, cultural considerations - particularly in Asia - necessitate nuanced communication approaches. Serious illness conversations have been shown to improve patient well-being; however, further research is needed to optimize these discussions, address unfinished business, and promote equitable access to prognostic dialog, particularly for vulnerable populations. Enhancing prognostic communication is critical for facilitating shared decision-making and improving the quality of EOL care.
AB - Accurate prognostic information is crucial for guiding end-of-life (EOL) decision-making in advanced cancer care. Although the European Society for Medical Oncology (ESMO) recommends using clinicians' prediction of survival (CPS) as an initial reference, CPS alone often lacks precision. This review synthesizes current prognostic models and the dialog surrounding EOL survival prediction. For patients with an expected survival of months, several validated prognostic tools are available, including measures such as the Eastern Cooperative Oncology Group Performance Status, the modified Glasgow Prognostic Scale, and comprehensive models such as the Supportive and Palliative Care Indicator Tool and the adaptable prognosis prediction model. When survival is expected to be weeks, the Palliative Performance Scale serves as a key assessment tool, while models such as the Palliative Prognostic Index and Prognosis in Palliative Care Study models are helpful. In the final days of life, clinicians primarily rely on observable physical indicators, including decreased consciousness and specific breathing patterns, whereas the surprise question has demonstrated limited predictive utility in this context. While most patients with advanced cancer express a desire for prognostic information, cultural considerations - particularly in Asia - necessitate nuanced communication approaches. Serious illness conversations have been shown to improve patient well-being; however, further research is needed to optimize these discussions, address unfinished business, and promote equitable access to prognostic dialog, particularly for vulnerable populations. Enhancing prognostic communication is critical for facilitating shared decision-making and improving the quality of EOL care.
KW - advanced cancer
KW - decision making
KW - functional prognostication
KW - prognostication
UR - https://www.scopus.com/pages/publications/105015405351
U2 - 10.1093/jjco/hyaf090
DO - 10.1093/jjco/hyaf090
M3 - Review article
C2 - 40446094
AN - SCOPUS:105015405351
SN - 0368-2811
VL - 55
SP - 991
EP - 999
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 9
ER -